Mass general brigham launches two clinical trials to study haystack mrd ctdna as guide for post-surgical treatment for two cancer types

Secaucus, n.j. and boston , aug. 7, 2025 /prnewswire/ -- haystack oncology, a quest diagnostics (nyse: dgx) company, today announced a research collaboration with mass general brigham investigators at massachusetts eye and ear and massachusetts general hospital, world-renowned centers for head and neck and advanced cutaneous oncology.
DGX Ratings Summary
DGX Quant Ranking